Howard W. Robin Sells 87,500 Shares of Nektar Therapeutics (NKTR) Stock
Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 87,500 shares of the business’s stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $17.06, for a total transaction of $1,492,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Howard W. Robin also recently made the following trade(s):
- On Thursday, September 1st, Howard W. Robin sold 87,500 shares of Nektar Therapeutics stock. The stock was sold at an average price of $17.83, for a total transaction of $1,560,125.00.
- On Tuesday, August 16th, Howard W. Robin sold 11,817 shares of Nektar Therapeutics stock. The stock was sold at an average price of $17.56, for a total transaction of $207,506.52.
Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at 17.21 on Tuesday. The stock’s market cap is $2.35 billion. Nektar Therapeutics has a 1-year low of $9.92 and a 1-year high of $19.98. The company’s 50-day moving average is $18.14 and its 200-day moving average is $16.00.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $32.77 million for the quarter, compared to analyst estimates of $34.17 million. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 68.30%. Nektar Therapeutics’s revenue for the quarter was up 44.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.40) EPS. Equities analysts expect that Nektar Therapeutics will post ($1.11) EPS for the current fiscal year.
Several research firms have recently commented on NKTR. Piper Jaffray Cos. set a $25.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Saturday, October 1st. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 26th. Jefferies Group reissued a “buy” rating on shares of Nektar Therapeutics in a report on Thursday, September 8th. Finally, Brean Capital reissued a “buy” rating and issued a $23.00 target price on shares of Nektar Therapeutics in a report on Friday, September 30th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $21.75.
Several large investors have recently modified their holdings of NKTR. Norges Bank purchased a new stake in shares of Nektar Therapeutics during the fourth quarter worth approximately $35,961,000. Prudential Financial Inc. boosted its stake in shares of Nektar Therapeutics by 4.9% in the first quarter. Prudential Financial Inc. now owns 322,973 shares of the biopharmaceutical company’s stock worth $4,441,000 after buying an additional 15,100 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Nektar Therapeutics by 74.8% in the first quarter. BlackRock Inc. now owns 9,013 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 3,858 shares during the last quarter. BlackRock Group LTD boosted its stake in shares of Nektar Therapeutics by 8.9% in the first quarter. BlackRock Group LTD now owns 175,205 shares of the biopharmaceutical company’s stock worth $2,408,000 after buying an additional 14,340 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its stake in shares of Nektar Therapeutics by 1.7% in the first quarter. BlackRock Fund Advisors now owns 10,029,475 shares of the biopharmaceutical company’s stock worth $137,905,000 after buying an additional 171,759 shares during the last quarter. 96.91% of the stock is currently owned by institutional investors and hedge funds.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.